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This conference on artificial neural networks (ANNs) provided anopportunity to explore current and future strategies for the pre-
diction of outcomes for patients with prostate carcinoma. For exam-
ple, it is necessary to improve the selection process for prostate
biopsy for a patient with clinical factors that raise the suspicion of
prostate carcinoma and provide greater precision about possible out-
comes after treatment. This paper provides an overview of the role
that ANNs may play in the larger picture of prostate carcinoma
prognostication. It also presents personal insights garnered from over
a decade of clinical experience with staging questions for patients
with prostate carcinoma.1
Historic Perspective
Care for a cancer patient must address three fundamental issues: 1)
the diagnosis, 2) the extent of disease, and 3) the appropriate treat-
ment. If a cancer poses a threat to the patient, and if treatment is
effective in some but not all patients, then the assessment of the
extent of the disease is a prerequisite for the logical pursuit of treat-
ment decisions. In general, of all prognostic factors, a description of
the extent of a disease is the most powerful predictor of patient
survival.2 The extent of a disease has been described historically by
stages, with increasing tumor burden or spread designated by a
higher stage and associated with a diminished survival. The tumor,
lymph node, metastasis (TNM) classification was developed in the
1950s, and it has been refined periodically.3–5 Within each reference
of T, N, or M, there are categories based on tumor size or extent,
number of regional lymph nodes containing metastases, and distant
metastases, referred to as “variables.”6 The assignment of a T, N, or M
variable is dependent on the quality of data obtained from staging
studies, such as a digital rectal examination (DRE) or a radionuclide
bone scan used for prostate carcinoma. A patient can then be de-
scribed by using a combination of all three variables. This places the
patient into an individual “bin” or category that is mutually exclusive
and exhaustive. For example, in prostate carcinoma, there are 16 bins
based on the possible permutations of the TNM variables (4 3 2 3 2
5 16 variables). For ease of use, these bins often are grouped together
into “stage groups” based on similar risk for a survival (Fig. 1).
An advantage of the bin model is that it allows for a relatively
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precise description of the extent of a patient’s cancer,
but a major disadvantage of the bin model arises from
the exponential increase in the number of bins with
the inclusion of additional variables. For patients with
prostate carcinoma, adding just one variable, such as
the histologic tumor grade (well, moderate, or poorly
differentiated), results in the creation of 48 bins (4 3
2 3 2 3 3 5 48 variables). One proposed strategy to
clarify this complexity is the further expansion of stage
grouping. However, the situation then becomes so
complicated that it becomes impractical. In addition,
the current stage grouping using only the TNM ana-
tomic extent of disease yields four stages, but most of
the recently identified prostate carcinomas fall into
clinically localized disease or Stage II. Dr. Alan Partin
has presented data that 97% of Dr. Patrick Walsh’s
patients at Johns Hopkins Hospital are categorized as
Stage II.
One disadvantage of any staging classification is
that an individual’s stage may change if new data
become available. For example, improvements in im-
aging technology, more precise histologic evaluation,
and better identification of micrometastases may
change an individual’s stage classification. This artifi-
cial “stage migration” of patients, for example, from a
T2N0M0 to a T3N0M0 or a T2N1M0, may well change
the survival prediction on which staging rules were
employed and, thus, undermine the reliability of the
staging system.2,6 Stage migration certainly is present
in prostate carcinoma using transrectal ultrasound
(TRUS) needle biopsy of seminal vesicles, step-sec-
tioning reconstruction of the entire prostate to iden-
tify microscopic capsular penetration, or identifica-
tion of micrometastases in the lymph nodes.
Such limitations in the staging classification do
not imply a lack of value in the description of the
anatomic extent of disease. Additional research may
contribute to survival prediction or treatment success.
Practitioners caring for prostate carcinoma patients
are fortunate to have two other strong prognostic fac-
tors: prostate specific antigen (PSA) and Gleason
score. In most studies evaluating prognostic factors,
pretreatment PSA level and Gleason score have been
shown to be strongly associated with disease outcome.
Recent studies focus on how to incorporate additional
information from these factors into a workable system
for clinical use. An important observation from the
1980s is pertinent when one devises a staging or prog-
nostication system; the National Cancer Institute rec-
ognized the impetus to evolve to a TNM staging sys-
tem from the classic Whitmore system by establishing
a “blue-ribbon” panel in 1986 to incorporate the best
of both systems. Unfortunately, the classification was
complex, and deliberations did not incorporate the
responsible agencies worldwide for staging classifica-
tions.7 Without the support of vital organizations, such
as the International Union Against Cancer (UICC) and
the American Joint Committee on Cancer (AJCC), the
system was not successful. In 1992, a broadly sup-
ported classification became available that modified
the TNM system to more closely reflect the general
categories outlined by Catalona and Whitmore.8 This
classification defined Stage A as clinically latent pros-
tate carcinoma (T1); Stage B as clinically manifest,
early prostate carcinoma (T2); Stage C as clinically
manifest, locally advanced prostate carcinoma (T3);
and Stage D as clinically manifest, advanced prostate
carcinoma with evidence of distant metastases (N1,
M1).9,10 The TNM system, as defined in 1992 and
modified in 1997, is now used broadly worldwide for
both clinical care and research studies.11 To be ac-
cepted universally by the medical community, a stag-
ing or prognostic system must be both practical and
supported by existing governing organizations.
Recent Investigations
Patients, clinicians, and researchers need methods
with which to evaluate how well an intervention
works. Modeling is a process by which statisticians
attempt to describe and summarize the clinical milieu
by using mathematical equations. The TNM staging
classification, in fact, is a simple prognostic model.
More complicated prognostic models, such as the Par-
tin, D’Amico, or Kattan nomograms described below,
are an improvement on the clinical staging model.12–14
In general, there are two purposes for constructing
models: to identify factors that are associated with an
outcome of interest and to predict a specific outcome,
such as survival.
No less than 13 prognostic classic statistical (lin-
ear or log-linear) models providing probabilities for a
FIGURE 1. TNM bin model for prostate carcinoma.
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specific prostate carcinoma treatment outcome have
been described as of 1998.15 The Partin nomograms,
which were published in 1993 and were expanded
with a larger data set in 1997, apply to patients with
clinically localized disease who are undergoing radical
prostatectomy and include clinical T stage, PSA level,
and Gleason score as variables.12 Nomograms were
developed on the basis of multivariate regression anal-
yses, with the endpoint of pathologic disease stage at
the time of radical prostatectomy. In 1987, Pasanski et
al. developed a prognostic index for prostate carci-
noma patients prior to external radiation therapy.16
D’Amico and colleagues have been prolific in refining
models: They developed a risk score that calculated
cancer volume in 1998 and a nomogram in 1999 for
use in patients undergoing either radical prostatec-
tomy or external radiation therapy.13,17–19 A nomo-
gram developed by Kattan and colleagues in 1998
utilizes a scoring system to provide a probability figure
for PSA recurrence after radical prostatectomy.14 More
recently, Vollmer and Montana evaluated models for
patients undergoing external radiation therapy using
clinical stage, PSA level, and Gleason score as vari-
ables.20 The natural log (PSA) for PSA values, T1 and
T2 versus T3 and T4, and Gleason score , 7 versus
Gleason score $ 7 were optimal cut points for assess-
ing the best performance in the models. Although the
sensitivity, specificity, and accuracy appeared quite
good, it was noteworthy that only 18% of the variance
was explained by these variables. The authors con-
cluded that additional prognostic factors are needed
for better prediction. Thus, recent nomograms are
helpful, and many are available on the Internet; how-
ever, these nomograms are less than ideal, because
PSA and Gleason score are categorized at different cut
points rather than as continuous variables, and the
addition of other factors would require complete re-
structuring of the nomogram.
ANNs are another means with which to model
outcome data.21 Briefly, ANNs are a class of nonlinear
mathematical models that are characterized by a com-
plex structure of interconnected computational ele-
ments, the neurons. These computational elements
then aggregate a series of inputs (prognostic factors)
using a summation operation and produce an output,
such as the probability of having a 10-year survival.
Inputs to each neuron are multiplied by a weight
factor that reflects the excitatory or inhibitory strength
of the connection from the input source to the neuron.
The sum of the weighted inputs plus a bias term then
goes through an activation function that behaves like
a “switch” to determine whether or not the neuron will
“fire” and, thus, will send out an output signal. The
bias term may be viewed as the threshold that the
weighted sum of inputs must exceed before the neu-
ron sends out an output signal. The information-pro-
cessing capacity of an ANN is a function of the type
and quantity of neurons in a given network and by the
arrangement of interconnections between neurons.
The “knowledge” or the “processing capability” of an
ANN is defined by the actual values of the connection
weights between neurons in the network. Such
“knowledge” of an ANN is acquired through a “learn-
ing phase,” during which examples of data to be pro-
cessed repeatedly are fed through the ANN model, and
the connection weights in the ANN are adjusted adap-
tively for the ANN as a whole to satisfy some prede-
termined performance goals.
Reports on “staging” ANNs have been published,
and several more have been presented at confer-
ences.22,23 Whereas classic statistical models are capa-
ble of identifying significant independent prognostic
factors and also can predict outcomes fairly well,
ANNs have been limited primarily to predicting out-
comes. Which is the preferred method? The classic
statistical methods have an advantage, in that they are
“transparent,” whereas ANNs essentially are a “black
box.” Nevertheless, one can argue that how these
models achieve their goal is less important than how
well they do it. After all, what is important to the
clinician and the patient is which model best predicts
the outcome of interest. A receiver operating charac-
teristics curve is an appropriate test with which to
compare how well the various models perform as risk-
assessment tools. The data presented at this confer-
ence suggest that there is a modest advantage with
some ANNs.
For all statistical modeling processes, having more
data available during the development phase will
strengthen the precision and reliability of its outcome
estimate. Fortunately, in urologic oncology, there is an
excellent example of the value of a large data set. For
years, there has been controversy about the prediction
of disease recurrence after chemotherapy for patients
with metastatic testis carcinoma to define low, inter-
mediate, and high risk patients. The analysis of an
international data set incorporating more than 5000
patients from leading institutions essentially resolved
the arguments and presented a system that is ac-
cepted worldwide.24 This process demonstrates the
tremendous utility of a large, diverse data set from
many key investigators with the support of interna-
tional governing bodies, thus ensuring the acceptance
of the final outcomes.
Problems Unique to Prostate Carcinoma
More specific problems with prostate carcinoma be-
come apparent as we evaluate clinical situations. Sev-
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eral general problems with prognostic factors dis-
cussed elsewhere in the conference relate to 1)
heterogeneity and sampling issues, 2) interobserver
variability, 3) sample size and subgroup analyses, 4)
specimen handling, and 5) endpoints and surrogate
biomarkers. For example, information from core biop-
sies of the prostate for the diagnosis of patients with
prostate carcinoma provides potential prognostic in-
formation. Variability in the data includes the number
of cores sampled (1 vs. 6 vs. 14), whether the biopsy is
directed at an “abnormal” area on DRE or TRUS, the
use of systematic biopsies, the number of positive
cores, the amount of the cancer present measured by
the percentage of tissue involved or amount (in milli-
meters) involved, the use of inked margins, and cost
issues relating to processing each core separately.25–32
Such concerns are by no means trivial issues and can
influence widespread acceptance of a system that in-
corporates the data provided by biopsies. Another rec-
ognized problem in prostate carcinoma is interob-
server variability in the grading. Expert pathologists
tend to grade higher than community-based physi-
cians with less experience.33
Tissue sampling for special studies is an addi-
tional problem. Most molecular markers require fro-
zen tissue harvested primarily from larger tumors
from biopsies or radical prostatectomy specimens,
thus introducing bias in a study. Microarrays for gene
analysis also are subject to such bias.
Additional problems include the use of subgroups
in prostate carcinoma. Endorectal magnetic reso-
nance imaging may prove to be useful primarily only
in patients who have larger tumors and, thus, are at
greater risk for extracapsular extension.34 In the Uni-
versity of Michigan data base, bladder neck-sparing
radical prostatectomy was associated with a greater
risk for a positive margin in patients with intermedi-
ate-sized tumors but not in patients with small or
large tumors.35
Finally, the radical prostatectomy specimen poses
several problems. Variability in the time between re-
moval of the prostate and retrieval of the tumor for
molecular biology studies may lead to variability in
results. The surgical technique may influence margin
status, which is recognized as an important prognostic
factor.36 The processing in pathology of the prostate
varies from routine sampling to a more extensive sam-
pling directed at an abnormal area to a step-section-
ing reconstruction to a wholemount reconstruction.
Each of these methods provides progressively more
precise information on the size and extent of the tu-
mor. In addition, quantification of the amount of ex-
traprostatic extension or a positive margin is not stan-
dardized.37 The widespread use of neoadjuvant
androgen-deprivation therapy is of unproven long
term benefit, but it drastically alters the histologic
findings in prostatectomy specimens and essentially
eliminates the possibility of further studies with most
molecular biomarkers.38
Approximately 30 prognostic factors have been
proposed for prostate carcinoma, a figure probably
less than half of those identified for breast carcinoma,
reflecting more intense research and greater national
funding for breast carcinoma. Expansion of prostate
carcinoma research may intensify the similar dilemma
currently noted in breast carcinoma, i.e., how to use
the new data.
What Is Needed Presently?
A risk-assessment tool is needed that produces a prob-
ability estimate for a specific outcome tailored for a
particular patient and therapy. The prognostic factors
included in such a tool need to explain most of the
variability in outcome.39 This information can then be
discussed with the patient in the context of patient
preference to accept or avoid specific side effects of
treatment. All current therapies for patients with pros-
tate carcinoma have side effects, and the patient must
always occupy the center of the discussion about their
relative importance. Randomized clinical trials in
prostate carcinoma patients have proven remarkably
difficult to complete based on a variety of factors,
including preconceived biases by physicians, difficulty
in patient randomization with widely disparate treat-
ments, and inadequate educational tools about the
studies for both the patient and the physician. How-
ever, the absence of optimal, randomized trials should
not preclude the use of the large amount of data
available on patients who have been treated around
the country, reflecting the real world. Matching of
such patients by prognostic factors in large data bases
may be tremendously valuable. The UICC and the
AJCC always have been interested in predicting sur-
vival. This is the primary purpose for clinical and
pathologic staging. In an era of rapidly growing appli-
cations for biomarkers, new factors to predict prostate
carcinoma outcomes frequently are identified; simple
clinical or pathologic staging will no longer suffice, nor
will simple models involving two or three variables.
Both classical statistical models and ANNs are amena-
ble to computer technology. Both forms of models can
be developed so that entering certain variables will
allow the computer to generate a probability for a
specific outcome. In our opinion, the probability fig-
ure should be a continuous variable, but the UICC and
the AJCC can develop categories based on increasing
risk for failure (or success). Such a probability figure,
with or without “risk” grouping, may be more helpful
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to the clinician who often is confronted by an increas-
ing number of so-called prognostic factors, not the
least of which is staging. This probability or grouping
can then be applied to the various outcomes, includ-
ing survival, complications, disease recurrence, etc.
The UICC and the AJCC must change their role
from the standardization of staging to the standard-
ization of risk assessment. Soon, a plethora of risk-
assessment packages for various cancers will be devel-
oped through industry and will become available on
the Internet. The UICC and the AJCC should lead the
way by facilitating the development of large, interna-
tional data sets, the promulgation of standards, and
the dissemination of information.
Microarrays for gene expression and tissue mi-
croarrays for biomarkers will provide an enormous
amount of raw data for an individual cancer and
present a tremendous challenge to our ability to pro-
cess the information. A true “prediction” with absolute
certainty about an outcome currently is beyond our
grasp; nevertheless, improved statistical models, such
as ANNs, may allow for greater flexibility and precision
and may bring us closer to the ultimate goal.
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